Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands
Source: Dr. Yi Chen  (3/13/26)
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note. More >

Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026"
Source: Dr. Douglas Loe  (3/9/26)
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts. More >

CleanTech Company Advances FDA-Cleared Solution Toward Big Gains
Source: Streetwise Reports  (2/10/26)
Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives. More >

Clean Tech Developer Sees Massive Opportunity in PFAS Treatment
Source: Streetwise Reports  (1/29/26)
BioLargo Inc. (BLGO:OTCQX) announces that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been installed in New Jersey. Find out why the company sees massive upside for its products. More >

Environmental Firm Finds High-Value Position in PFAS Remediation Industry
Source: Streetwise Reports  (1/28/26)
BioLargo Inc. (BLGO:OTCQX) has announced the installation of its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system in New Jersey. Discover why the company anticipates significant potential for its products. More >

Biotech Co. Expands Testing Tied to its Cell Pouch Bio-hybrid Organ
Source: Dr. Douglas Loe  (1/13/26)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) seeks to determine how a newly developed immunosuppressive agent and, separately, how a different type of islet will work in conjunction with cell implantation via its proven Cell Pouch Bio-hybrid Organ, noted a Leede Financial Inc. report. Read on to learn more about what this Speculative Buy-rated company is working on. More >

Analyst: Scientific Instrument Co.'s Q3/25 Results 'Soft'
Source: Dr. Douglas Loe  (12/2/25)
Nanalysis Scientific Corp. (NSCI:TSX.V; NSCIF:OTC; 1N1:FSE) has its price target lowered as a result, but is expected to improve its financials in the near term, noted a Leede Financial Inc. report. More >

Clean Tech Co.: Wound Care Subsidiary Set to Take Off; 3Q Results
Source: Streetwise Reports  (11/19/25)
Clean technology innovation company BioLargo Inc. releases its financial and operational results for the three- and nine-month periods ending September 30. It also has announced an agreement to distribute its cutting-edge wound irrigation solution nationally. More >

Cleantech Co. Advances Antimicrobial Wound Care Breakthrough
Source: Streetwise Reports  (10/17/25)
Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies is making significant strides. Read why one analyst says the technology is on "the cusp of commercialization." More >

Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough
Source: Streetwise Reports  (10/2/25)
Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings about its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution. Read to discover why one expert thinks the breakthrough is important to the company's future. More >

Medical Co.'s New Joint Venture Could Expand Co.'s Footprint
Source: Dr. Douglas Loe  (8/13/25)
Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating. More >

Cleantech/Life Sciences Co. Advances Products in Q2/25
Source: Richard Ryan  (8/4/25)
BioLargo Inc. (BLGO:OTCQX) enters into several agreements, forms partnerships and receives third party product validation, noted an Oak Ridge Financial report. More >

Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis  (7/14/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report. More >

Analyst Shares Thoughts After Microdisplay Co.'s Demo Day
Source: Jaeson Schmidt  (6/23/25)
Kopin Corp.'s (KOPN:NASDAQ) display and optical technologies as well as its products are impressive, noted a Lake Street Capital Markets report. More >

Biotech Boasts Compelling Pipeline
Source: Dr. Andre Uddin  (6/23/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) is exploring financing options with some potential sources of capital, noted a Research Capital Corp. report. More >

Interim Data From TID Trial Are Positive
Source: Streetwise Reports  (5/15/25)
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit. More >

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis  (4/28/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report. More >

Regenerative Medicine Firm OK'd To Advance Trial in T1D
Source: Streetwise Reports  (4/3/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication. More >

Cell Pouch Co. Peer Aborts Program Using Like Device
Source: Dr. Douglas Loe  (4/3/25)
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report. More >

Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth
Source: Streetwise Reports  (4/1/25)
BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story. More >

FDA OKs Trial of Cell Reservoir in Thyroid Disease
Source: Dr. Douglas Loe  (3/10/25)
In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report. More >

Kentucky Medical Co. Has Strong Operating Fundamentals
Source: Douglas Loe  (2/12/25)
Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note. More >

AI Stock in an Uptrend That Is Likely To Continue
Source: Clive Maund  (2/10/25)
Technical Analyst Clive Maund explains why he thinks Light AI Inc. (ALGO:CBOE) is an Immediate Strong Buy. More >

Healthcare Pioneer Expands Revolutionary Treatment Platform
Source: Streetwise Reports  (2/6/25)
Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Cell Pouch technology. One analyst says it is the "most advanced encapsulation device in development." More >

Biotech Requests OK to Assess Device in Second Indication
Source: Dr. Joseph Pantginis  (2/6/25)
The company behind this possible "pipeline in a device" wants to evaluate it now in thyroid disease after having begun with trials in type 1 diabetes, noted an H.C. Wainwright & Co. report. More >